Given the preponderance of data that links nuclear IGF-1R to worse outcomes after IGF-1R - directed treatments, inhibiting nuclear translocation of IGF-1R or inhibiting its sequestration in the nucleus could re-sensitize tumor cells to treatment. Here, IGF1R is linked to neoplasm.